Research Article
Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
Figure 1
Histopathology feature of HCC xenografts in various treatment groups (H&E stain); thick arrows: pleomorphic tumor giant cells. (a) Ctrl: control, (b) Sora: sorafenib, (c) hpMSC (IV): human placenta-derived mesenchymal stem cells (intravenous administration), (d) hpMSC (local): hpMSC (local administration), (e) hpMSC (IV) + Sora, and (f) hpMSC (local) + Sora. HCC: hepatocellular carcinoma.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |